A Phase 2 interventional study of Memantine and Placebo in Memory Disorder, Retention Disorder, Cognitive and Subjective Cognitive Impairment, sponsored by Merz Pharmaceuticals GmbH. Completed at 14 sites in 2 countries. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-11-27.
Sponsored by Merz Pharmaceuticals GmbH (part of Merz Pharma) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Memory Disorders with a site in Germany — 1 open to participants now, 2 under way, none of them phase 3. Memory Disorders · Germany.
Among the 13 studies in Memory Disorders with a site in Germany, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2010, is one of 4 in phase 2, and was the 4th registered.
373 studies on the registry are indexed under Memory Disorders; 67 are open to participants now.
Browse Memory Disorders studies →1 of the 13 studies in Memory Disorders with a site in Germany is open now. Recruiting first, the newest first:
BDH-Klinik Hessisch Oldendorf · Sites in Germany
Ages 18–70
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 54 Memory Disorders studies recruiting now, 27 (50%) set no upper age limit and 13 (24%) stop at 75 or younger; 3 take children under 18; 22 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 299 is above the median of 72 across 298 interventional studies indexed under Memory Disorders.
Median enrollment 205 across the 10 interventional studies, 180 across the 3 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 13 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merz Pharmaceuticals GmbH, one of the names counted as Merz Pharma. Under that name alone:
Merz Pharmaceuticals GmbH is the lead sponsor of 61 studies on the registry; none are open to participants now.
Merz Pharma has 1 study filed under Memory Disorders — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Memory Disorders with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, memantine will be tested in a new indication: in the treatment of subjective memory, concentration, or attention problems (subjective cognitive impairment) in the absence of dementia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Memantine
Drug: Placebo
Each subject will receive memantine 10mg tablets once daily
Each subject will receive matching placebo tablets once daily
"Patient Global Impression of Change" (PGI-C) at visit 4
It is the statistical comparison between the placebo group and the memantine group.The group comparison will be performed by the use of an analysis of covariance (ANCOVA) model.
Time frame: 12 weeks
Change from baseline to visit 3 and 5 of Patient Global Impression of Change (PGI-C)
Time frame: 16 weeks
Change from baseline to visit 4 in "Everyday Cognition 39" (ECog 39) total score
Time frame: 12 weeks
Change from baseline to visit 4 in "Hospital Anxiety and Depression Scale" (HADS) Score
Time frame: 12 weeks
Change from baseline to visit 3, 4, 5 of "Computer-based Neuropsychological Test Battery (C-NTB) by CogState Ltd.
Time frame: 16 weeks
The record gives a start of Nov 2010, a primary completion of Aug 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Memantine